Safety and efficacy of REP 2139 and pegylated interferon alfa-2α for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial (vol 2, pg 877, 2017)

被引：0

作者：

Bazinet, M.

Pantea, V

Cebotarescu, V

机构：

来源：

LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：E1 / E1

页数：1

共 40 条

[21] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Kwo, Paul Y.
Lawitz, Eric J.
McCone, Jonathan
Schiff, Eugene R.
Vierling, John M.
Pound, David
Davis, Mitchell N.
Galati, Joseph S.
Gordon, Stuart C.
Ravendhran, Natarajan
Rossaro, Lorenzo
Anderson, Frank H.
Jacobson, Ira M.
Rubin, Raymond
Koury, Kenneth
Pedicone, Lisa D.
Brass, Clifford A.
Chaudhri, Eirum
Albrecht, Janice K.
LANCET, 2010, 376 (9742): : 705 - 716
[22] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)
Kwo, P. Y.
Lawitz, E. J.
McCone, J.
LANCET, 2010, 376 (9748): : 1224 - 1224
[23] Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial (vol 383, pg 515, 2014)
Lawitz, E.
Poordad, F. F.
Pang, P. S.
LANCET, 2014, 383 (9920): : 870 - 870
[24] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Jacobson, Ira M.
Dore, Gregory J.
Foster, Graham R.
Fried, Michael W.
Radu, Monica
Rafalsky, Vladimir V.
Moroz, Larysa
Craxi, Antonio
Peeters, Monika
Lenz, Oliver
Ouwerkerk-Mahadevan, Sivi
De La Rosa, Guy
Kalmeijer, Ronald
Scott, Jane
Sinha, Rekha
Beumont-Mauviel, Maria
LANCET, 2014, 384 (9941): : 403 - 413
[25] Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Molina, Jean-Michel
Orkin, Chloe
Iser, David M.
Zamora, Francisco-Xavier
Nelson, Mark
Stephan, Christoph
Massetto, Benedetta
Gaggar, Anuj
Ni, Liyun
Svarovskaia, Evguenia
Brainard, Diana
Subramanian, G. Mani
McHutchison, John G.
Puoti, Massimo
Rockstroh, Juergen K.
LANCET, 2015, 385 (9973): : 1098 - 1106
[26] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (vol 384, pg 403, 2014)
Jacobson, I. M.
Dore, G. J.
Foster, G. R.
LANCET, 2016, 387 (10030): : 1816 - 1816
[27] EFFICACY AND SAFETY OF BULEVIRTIDE IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS DELTA: PRIMARY ENDPOINT RESULTS FROM A PHASE 2b OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY MYR204
Asselah, Tarik
Lampertico, Pietro
Wedemeyer, Heiner
Streinu-Cercel, Adrian
Pantea, Victor
Lazar, Stefan
Placinta, Gheorghe
Gherlan, George Sebastian
Bogomolov, Pavel
Stepanova, Tatiana
Morozov, Viacheslav
Chulanov, Vladimir
Syutkin, Vladimir E.
Sagalova, Olga
Gorodin, Vladmir
Manuilov, Dmitry
Mercier, Renee-Claude
Ye, Lei
Flaherty, John F.
Osinusi, Anu O.
Lau, Audrey H.
Da, Ben L.
Bourliere, Marc
Ratziu, Vlad
Pol, Stanislas
Hilleret, Marie-Noelle
Zoulim, Fabien
HEPATOLOGY, 2024, 79 (02) : E43 - E44
[28] Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: Primary endpoint results from the phase 2b, open-label, randomized, multicenter study MYR204
Asselah, Tarik
Lampertico, Pietro
Wedemeyer, Heiner
Streinu-Cercel, Adrian
Pantea, Victor
Lazar, Stefan
Placinta, Gheorghe
Gherlan, George Sebastian
Bogomolov, Pavel
Stepanova, Tatyana
Morozov, Viacheslav
Chulanov, Vladimir
Syutkin, Vladimir
Sagalova, Olga
Gorodin, Vladimir
Manuilov, Dmitry
Mercier, Renee-Claude
Ye, Lei
Flaherty, John F.
Freismuth, Aurelie
Osinusi, Anu
Lau, Audrey
Da, Ben
Bourliere, Marc
Ratziu, Vlad
Pol, Stanislas
Hilleret, Marie-Noelle
Zoulim, Fabien
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 104 - 105
[29] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Sulkowski, Mark
Hezode, Christophe
Gerstoft, Jan
Vierling, John M.
Mallolas, Josep
Pol, Stanislas
Kugelmas, Marcelo
Murillo, Abel
Weis, Nina
Nahass, Ronald
Shibolet, Oren
Serfaty, Lawrence
Bourliere, Marc
Dejesus, Edwin
Zuckerman, Eli
Dutko, Frank
Shaughnessy, Melissa
Hwang, Peggy
Howe, Anita Y. M.
Wahl, Janice
Robertson, Michael
Barr, Eliav
Haber, Barbara
LANCET, 2015, 385 (9973): : 1087 - 1097
[30] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (vol 385, 1087, 2015)
Sulkowski, M.
Hezode, C.
Gerstoft, J.
LANCET, 2015, 385 (9973): : 1074 - 1074

← 1 2 3 4 →